At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. In 2017, our products reached well over 500 million patients and our aspiration is to reach 1 billion people.
In addition to the global No. 1 ranking in biosimilars, Sandoz, a Novartis company, holds leading global positions in areas ranging from generic cardiovascular, central nervous system (CNS), pain and ophthalmology to oncology, respiratory and hormonal therapeutics.
Whether the cause be an aging population, changing lifestyle patterns or poor economic outlook, healthcare systems around the world are struggling to cope with the reality of increasing cost containment pressures. But this challenge is not without a solution: generic pharmaceuticals provide significant savings for patients and healthcare systems alike. Generics free up resources for the funding of costlier novel therapies, benefiting patients and incentivizing investment in new, innovative medicines that target unmet medical needs. Sandoz plays an important role in the healthcare system.
A trusted partner of healthcare professionals, Sandoz Canada has a network of suppliers that stand out for their reliability and high-quality standards. Our dedicated sales force is distinguished by the strong business relationships it has with customers and the excellent service it provides. Our broad product line falls into four business segments: Generic medicines, Biosimilars, Specialty Products and Consumer Products (available without prescription).
A proven track record across the globe:
We have strong scientific roots that have driven many medical innovations, from the first oral penicillin in 1951 to the first biosimilars in Europe and the US; new delivery technologies (e.g. our award-winning Forspiro inhaler or our Fentanyl patch technology) offer genuine improvements over alternative market offerings. We go beyond providing standard products and add value to the healthcare system through a range of support services and value-added medicines including combination formulations. Examples include the “Sandoz Pro” healthcare professionals app pioneered by Sandoz Canada and the “three-in-one” cardiovascular “polypill” launched by Sandoz Germany in 2015.
Increasing access to medicine is the basis of our day-to-day business model, but we also run a range of targeted corporate responsibility programs to ensure access for those most in need. These programs aim to address specific health needs in underprivileged communities, promote access to medical information and help build capacity.